Evofem Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOFEM BIOSCIENCES, INC. | ||
| March 27, 2024 | By: | /s/ Saundra Pelletier |
|---|---|---|
| Name: | Saundra Pelletier | |
| Title: | President, Chief Executive Officer and Interim Chairperson of the Board |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Saundra Pelletier | President, Chief Executive Officer and Interim Chairperson of the Board | March 27, 2024 |
| Saundra Pelletier | (Principal Executive Officer) | |
| /s/ Ivy Zhang | Chief Financial Officer and Secretary | March 27, 2024 |
| Ivy Zhang | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Kim P. Kamdar, Ph.D. | Director | March 27, 2024 |
| Kim P. Kamdar, Ph.D. | ||
| /s/ Tony O’Brien | Director | March 27, 2024 |
| Tony O’Brien | ||
| /s/ Colin Rutherford | Director | March 27, 2024 |
| Colin Rutherford | ||
| /s/ Lisa Rarick | Director | March 27, 2024 |
| Lisa Rarick | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.